Thank you, Lisa, and thanks for joining us. The biopharmaceutical and Diagnostic Solutions segment delivered another solid year with double-digit top line growth for fiscal 2025. Revenue growth in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results